Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02721134Not ApplicableCompleted

Diagnostic Performance of a New Bio-marker During Bacterial Sepsis

Role: collaborator

NCT02707718Completed

Biomarkers for the Early Identification of Sepsis in the Emergency Department

Role: collaborator

NCT02401555Completed

Performance Evaluation of the Bio-Rad Geenius HIV1/2 Supplemental Assay

Role: lead

NCT01226173Completed

Dengue Virus NS1 Antigen (Bio-Rad) Clinical Protocol

Role: lead

All 4 trials loaded